Icotyde™ FDA approval

Icotyde™(icotrokinra)-FDA Approval

On march 18 Johnson & Johnson announced that the U.S Food and Drug Administration(FDA) has approved Icotyde™(icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.

Things to note with new Icotyde™(icotrokinra) therapy:

- One daily unique dose of 200mg
- Tuberculosis test is recommended but not required. Left to the physician's discretion
- Bridge available for commercially insured patients

Read the press release:
J&J press release
Icotyde™(icotrokinra)-Prescription Information:
Icotyde-PI